BCDA BioCardia Inc

Price (delayed)

$0.346

Market cap

$9.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$9.73M

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's ...

Highlights
The EPS has grown by 27% YoY and by 15% from the previous quarter
The debt has declined by 21% year-on-year and by 7% since the previous quarter
BCDA's quick ratio has plunged by 80% YoY and by 22% from the previous quarter
BioCardia's gross profit has plunged by 65% YoY

Key stats

What are the main financial stats of BCDA
Market
Shares outstanding
27.3M
Market cap
$9.45M
Enterprise value
$9.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
18.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.78
Earnings
Revenue
$468,000
EBIT
-$10.34M
EBITDA
-$9.92M
Free cash flow
-$8.95M
Per share
EPS
-$0.47
Free cash flow per share
-$0.36
Book value per share
-$0.09
Revenue per share
$0.02
TBVPS
$0.11
Balance sheet
Total assets
$2.68M
Total liabilities
$4.95M
Debt
$1.23M
Equity
-$2.28M
Working capital
-$2.81M
Liquidity
Debt to equity
-0.54
Current ratio
0.31
Quick ratio
0.25
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-2,119.9%
Gross margin
100%
Net margin
-2,208.8%
Operating margin
-2,224.1%
Efficiency
Return on assets
-261.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-2,208.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCDA stock price

How has the BioCardia stock price performed over time
Intraday
4.85%
1 week
-11.28%
1 month
-8.95%
1 year
-78.9%
YTD
-47.91%
QTD
-14.99%

Financial performance

How have BioCardia's revenue and profit performed over time
Revenue
$468,000
Gross profit
$468,000
Operating income
-$10.41M
Net income
-$10.34M
Gross margin
100%
Net margin
-2,208.8%
BioCardia's operating margin has shrunk by 150% YoY but it has increased by 9% QoQ
The net margin has dropped by 148% year-on-year but it has increased by 9% since the previous quarter
BioCardia's gross profit has plunged by 65% YoY
BioCardia's revenue has plunged by 65% YoY

Growth

What is BioCardia's growth rate over time

Valuation

What is BioCardia stock price valuation
P/E
N/A
P/B
N/A
P/S
18.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.78
The EPS has grown by 27% YoY and by 15% from the previous quarter
The equity has declined by 42% since the previous quarter
BCDA's P/S is 79% below its 5-year quarterly average of 90.4 and 62% below its last 4 quarters average of 48.9
BioCardia's revenue has plunged by 65% YoY

Efficiency

How efficient is BioCardia business performance
The ROS has plunged by 148% YoY but it has grown by 9% from the previous quarter
The ROA has plunged by 102% YoY and by 14% from the previous quarter

Dividends

What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCDA.

Financial health

How did BioCardia financials performed over time
BCDA's total assets is 46% lower than its total liabilities
BCDA's quick ratio has plunged by 80% YoY and by 22% from the previous quarter
BCDA's current ratio has shrunk by 77% YoY and by 23% QoQ
The debt is 154% greater than the equity
BioCardia's debt to equity has plunged by 166% YoY but it has increased by 34% from the previous quarter
The equity has declined by 42% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.